Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model
Abo sherif, M., Abo Shama, N., Mahmoud, S., El-Desouky, M., Hanna, D., Ali, M. (2024). Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model. EKB Journal Management System, 67(11), 597-602. doi: 10.21608/ejchem.2024.276701.9459
Mohamed E. Abo sherif; Noura M. Abo Shama; Sara H. Mahmoud; Mohamed A. El-Desouky; Demiana H. Hanna; Mohamed A. Ali. "Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model". EKB Journal Management System, 67, 11, 2024, 597-602. doi: 10.21608/ejchem.2024.276701.9459
Abo sherif, M., Abo Shama, N., Mahmoud, S., El-Desouky, M., Hanna, D., Ali, M. (2024). 'Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model', EKB Journal Management System, 67(11), pp. 597-602. doi: 10.21608/ejchem.2024.276701.9459
Abo sherif, M., Abo Shama, N., Mahmoud, S., El-Desouky, M., Hanna, D., Ali, M. Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model. EKB Journal Management System, 2024; 67(11): 597-602. doi: 10.21608/ejchem.2024.276701.9459

Immunogenicity of Vaccine Encoding Spike Protein against Middle East Respiratory Syndrome Coronavirus in Mammalian Model

Egyptian Journal of Chemistry
Volume 67, Issue 11, November 2024, Pages 597-602    PDF (600.51 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2024.276701.9459
Authors
Mohamed E. Abo sherif1; Noura M. Abo Shama2; Sara H. Mahmoud2; Mohamed A. El-Desouky1; Demiana H. Hanna1; Mohamed A. Ali* 2
1Department of chemistry, Faculty of Science, Cairo University, Giza, Egypt
2Center of Scientific Excellence for Influenza Viruses, Environmental Researches and Climate Changes Institute, National Research Centre, Giza, Egypt.
Abstract
Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) represents a major threat to human health worldwide. No licensed MERS-CoV vaccines or therapeutics were developed. So, the aim of the current study is the generation and immunological evaluation of DNA vaccine candidate against MERS-CoV. The spike gene was selected to generate the DNA vaccine, which encodes the spike protein of coronaviruses that plays a pivotal role in viral entry into host cells and serves as a primary target for host immune responses. Moreover, the antibody responses post-immunization with spike-DNA fragment and inactivated coronaviruses vaccines was explored, using a microneutralization assay with severe acute respiratory syndrome (SARS-CoV-2), and the log2 antibody titers at different time points (0, 2, 4, 6, and 8 weeks) post-vaccination was measured. The inactivated MERS-CoV and pCDNA3.1-S-MERS-CoV vaccines maintained steady log2 antibody titers, showing no specific response to SARS-CoV-2 in the control group (PBS). Microneutralization against MERS-CoV showed no significant antibody titers for Inactivated SARS-CoV-2, suggesting no cross-reactivity. Sustained antibody titers for Inactivated MERS-CoV indicate vaccine-induced stability. This study sheds light on antibody responses induced by these vaccines against MERS-CoV. These insights are crucial for optimizing vaccine strategies, particularly in the context of the evolving MERS-CoV pandemic.
Keywords
Vaccine; spike; MERS-CoV; SARS-CoV-2; antibodies
Statistics
Article View: 256
PDF Download: 76